Voro Therapeutics, Inc.
June 23, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Oncology
Voro Therapeutics is a privately held biotechnology company based in San Diego, spun out of Alloy Therapeutics’ 82VS Venture Studio. The company’s PrimeBody platform is a best-in-class conditionally-activated biologics technology that delivers systemic therapy with tissue-specific activation, achieving safe and durable anti-tumor responses. Voro’s lead asset, the first Fc-enhanced, high-affinity CD47 blocker, shows curative activity without the historical safety or exposure limitations of this target and is advancing through IND-enabling studies. Applicable to cytokines, TCEs, and ADCs, PrimeBody supports a diversified pipeline in oncology and immunology. Voro is led by experienced drug developers with deep expertise in conditionally-activated therapeutics.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2023
CEO
Ugur Eskiocak
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}